These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16108953)

  • 21. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study.
    Raivio MM; Laurila JV; Strandberg TE; Tilvis RS; Pitkälä KH
    Am J Geriatr Psychiatry; 2007 May; 15(5):416-24. PubMed ID: 17463191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current attitudes regarding treatment of agitation and psychosis in dementia.
    Serby MJ; Roane DM; Lantz MS; Cohen AJ; Turok A; Perlis TE
    Am J Geriatr Psychiatry; 2009 Feb; 17(2):174. PubMed ID: 19155750
    [No Abstract]   [Full Text] [Related]  

  • 23. Discontinuation of risperidone in Alzheimer's disease.
    Ling SM; Bonner AF; McMullen TL
    N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
    [No Abstract]   [Full Text] [Related]  

  • 24. Discontinuation of risperidone in Alzheimer's disease.
    Power GA
    N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
    [No Abstract]   [Full Text] [Related]  

  • 25. Discontinuation of risperidone in Alzheimer's disease.
    Gnjidic D; Hilmer SN
    N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
    [No Abstract]   [Full Text] [Related]  

  • 26. Discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Schultz SK; Sultzer DL
    N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
    [No Abstract]   [Full Text] [Related]  

  • 27. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospitalized patients with dementia: the dilemma of managing agitation.
    Bradas CM; Mion LC
    Geriatr Nurs; 2011; 32(6):455-8. PubMed ID: 22056123
    [No Abstract]   [Full Text] [Related]  

  • 29. Professional consensus on the treatment of agitation, aggressive behaviour, oppositional behaviour and psychotic disturbances in dementia.
    Benoit M; Arbus C; Blanchard F; Camus V; Cerase V; Clement JP; Fremont P; Guerin O; Hazif Thomas C; Jeanblanc F; Lafont C; Moreaud O; Pedra M; Poncet M; Richard Harston S; Rigaud AS; Sotto Martin ME; Touchon J; Vellas B; Fitten LJ; Robert PH
    J Nutr Health Aging; 2006; 10(5):410-5. PubMed ID: 17066213
    [No Abstract]   [Full Text] [Related]  

  • 30. Agitation and psychosis in dementia.
    Ballard C
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
    [No Abstract]   [Full Text] [Related]  

  • 31. Clozapine use in treatment-resistant agitation in the setting of dementia.
    Bastiampillai T; Dhillon R; French TH
    Aust N Z J Psychiatry; 2009 Jul; 43(7):689-90. PubMed ID: 19530027
    [No Abstract]   [Full Text] [Related]  

  • 32. Liquid risperidone in the treatment of psychotic agitation.
    Tsai C; Puzantian T
    CNS Drugs; 2002; 16(11):777; author reply 778. PubMed ID: 12383033
    [No Abstract]   [Full Text] [Related]  

  • 33. [Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage].
    Stoppe G; Schreiner A; Schmitt AB
    Dtsch Med Wochenschr; 2006 Mar; 131(9):423-9. PubMed ID: 16493564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)].
    Kudo T
    Seishin Shinkeigaku Zasshi; 2007; 109(7):657-63. PubMed ID: 17969953
    [No Abstract]   [Full Text] [Related]  

  • 35. To prescribe or not to prescribe? Atypical antipsychotic drugs in patients with dementia.
    Jeste DV; Meeks T
    South Med J; 2007 Oct; 100(10):961-3. PubMed ID: 17943030
    [No Abstract]   [Full Text] [Related]  

  • 36. Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances.
    Bies RR; Mulsant BH; Rosen J; Huber KA; Wilson NL; Kirshner MA; Pollock BG
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):87-91. PubMed ID: 16129385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involving the resident/decision maker in antipsychotic medication use.
    Mort JR
    S D Med; 2013 Apr; 66(4):148-9. PubMed ID: 23697039
    [No Abstract]   [Full Text] [Related]  

  • 38. Beware of over-interpreting negative trials.
    Scahill L; Aman MG; McCracken JT; McDougle CJ; Vitiello B
    J Autism Dev Disord; 2008 Oct; 38(9):1609-10. PubMed ID: 18594960
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
    Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical antipsychotics, elderly patients, and mortality risk.
    Citrome L
    South Med J; 2007 Oct; 100(10):964-5. PubMed ID: 17943033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.